Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Crosses Above 200 Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $46.83 and traded as high as $56.77. Global X Genomics & Biotechnology ETF shares last traded at $56.27, with a volume of 52,079 shares trading hands.

Global X Genomics & Biotechnology ETF Trading Up 2.4%

The firm’s 50 day simple moving average is $48.04 and its 200-day simple moving average is $46.83. The stock has a market capitalization of $63.02 million, a price-to-earnings ratio of -24.05 and a beta of 1.21.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors and hedge funds have recently bought and sold shares of GNOM. Creative Financial Designs Inc. ADV boosted its position in Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after purchasing an additional 481 shares during the last quarter. IFP Advisors Inc increased its position in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after purchasing an additional 489 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the last quarter. Wealth Management Partners LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 1st quarter worth approximately $244,000. Finally, Jane Street Group LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 7.7% during the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares in the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.